CXCR4 and cardiovascular disorder: Because systemic administration of plerixafor is associated with adverse effects, especially to patients with cardiovascular diseases, further development of CXCR4-tropic HIV-1 entry inhibitors with weaker affinity to CXCR4 than plerixafor is needed (Berg et al., 2018).